CLLS - Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today? | Benzinga
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company announced a research agreement with AstraZeneca Plc (NASDAQ: AZN)
AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities to design cell and gene therapy candidate products.
As part of the agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development.
AstraZeneca will have an option for a worldwide exclusive license on the ...